Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
| العنوان: | Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial |
|---|---|
| المؤلفون: | Véronique Dorvaux, Marc Delord, Marc Muller, Melanie Mercier, Hacene Zerazhi, Jacques Chapiro, Eric Jourdan, Laurence Legros, Françoise Rigal-Huguet, Iona Vaida, François Guilhot, Alberto Santagostino, Claude Preudhomme, Joelle Guilhot, Valérie Coiteux, Jean-Michel Miclea, Jean-Jacques Kiladjian, Emmanuel Gyan, Aude Charbonnier, Amélie Penot, Eric Deconinck, Franck E. Nicolini, Gabriel Etienne, Hyacinthe Johnson-Ansah, Jean-Claude Chomel, Kamel Ghomari, Nathalie Cambier, Delphine Lebon, Viviane Dubruille, Sylvie Glaisner, Philippe Rousselot, Loïc Fouillard, Alain Delmer, Bertrand Joly, Pascal Lenain, Claude-Eric Bulabois, Martine Escoffre Barbe, Christian Berthou, Isabelle Plantier, Delphine Rea, Marc G. Berger, Magda Alexis, Francois-Xavier Mahon, Pascale Cony-Makhoul, Ludovic Lhermitte, Lydia Roy, Jean-Michel Cayuela, Denis Caillot, Anne Vekhoff, Martine Gardembas, Bertrand Pollet, Agnès-Paule Guerci-Bresler, Yazid Arkam, Hervé Maisonneuve, Frédéric Maloisel |
| المساهمون: | Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA) |
| المصدر: | Leukemia Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-020-01117-w⟩ Leukemia, Springer Nature, 2021, ⟨10.1038/s41375-020-01117-w⟩ |
| بيانات النشر: | HAL CCSD, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Chronic myeloid leukaemia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Interferon, Internal medicine, Medicine, Adverse effect, ComputingMilieux_MISCELLANEOUS, business.industry, Imatinib, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, 3. Good health, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Major Molecular Response, Pegylated interferon alpha 2a, Toxicity, Cytarabine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug |
| الوصف: | The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 mg + pegylated interferon alpha2a (PegIFN-α2a) for the front-line treatment of chronic-phase chronic myeloid leukaemia (CML). Long-term analyses included overall and progression-free survival, molecular responses to treatment, and severe adverse events. Starting in 2003, the trial included 787 evaluable patients. The median overall follow-up of the patients was 13.5 years (range 3 months to 16.7 years). Based on intention-to-treat analyses, at 15 years, overall and progression-free survival were similar across arms: 85%, 83%, 80%, and 82% and 84%, 87%, 79%, and 79% for the IM 400 mg (N = 223), IM 600 mg (N = 171), IM 400 mg + AraC (N = 172), and IM 400 mg + PegIFN-α2a (N = 221) arms, respectively. The rate of major molecular response at 12 months and deep molecular response (MR4) over time were significantly higher with the combination IM 400 mg + PegIFN-α2a than with IM 400 mg: p = 0.0001 and p = 0.0035, respectively. Progression to advanced phases and secondary malignancies were the most frequent causes of death. Toxicity was the main reason for stopping AraC or PegIFN-α2a treatment. |
| اللغة: | English |
| تدمد: | 0887-6924 1476-5551 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e82d474ec7e8650bf9829473b30a0c5 https://hal.uca.fr/hal-03122967 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....8e82d474ec7e8650bf9829473b30a0c5 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 08876924 14765551 |
|---|